Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2024 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Expects to report topline results in 2025 from Phase 2a influenza A human challenge study with oral CC-42344, including initial indication of virologyIn vitro testing shows CC-42344 inhibits the avian...
September 05, 2023 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

BOTHELL, Wash., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing novel...
November 17, 2022 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

BOTHELL, Wash., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) today announced that CC-42344 demonstrated a favorable safety profile in both the single-ascending dose and...
October 14, 2021 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021

BOTHELL, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
June 28, 2021 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Joins Russell Microcap® Index

BOTHELL, Wash., June 28, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
June 14, 2021 08:30 ET | Source: Cocrystal Pharma, Inc.

Cocrystal’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants

BOTHELL, Wash., June 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
May 07, 2021 16:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Closing of $40 Million Bought Deal

BOTHELL, Wash., May 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
May 04, 2021 18:41 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock

BOTHELL, Wash., May 04, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
March 10, 2021 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Extends Drug Discovery Collaboration with HitGen and InterX

BOTHELL, Wash, March 10, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
March 02, 2021 11:28 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference [UPDATED]

BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...

Next Page keyboard_arrow_right